vs
Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and Nano Dimension Ltd. (NNDM). Click either name above to swap in a different company.
Nano Dimension Ltd. is the larger business by last-quarter revenue ($57.8M vs $37.2M, roughly 1.6× GYRE THERAPEUTICS, INC.). GYRE THERAPEUTICS, INC. runs the higher net margin — -3.7% vs -171.1%, a 167.4% gap on every dollar of revenue. GYRE THERAPEUTICS, INC. produced more free cash flow last quarter ($-5.8M vs $-21.1M).
GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.
Nano Dimension Ltd. is a leading provider of additively manufactured electronics solutions and 3D printing technologies. It designs high-precision 3D printers, related materials, and software for producing printed circuit boards, microelectronics components, and multi-layer electronic devices, serving aerospace, defense, medical, automotive, and industrial electronics segments across global markets.
GYRE vs NNDM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2024
| Metric | | |
|---|---|---|
| Revenue | $37.2M | $57.8M |
| Net Profit | $-1.4M | $-98.8M |
| Gross Margin | 95.3% | 43.1% |
| Operating Margin | 0.3% | -155.1% |
| Net Margin | -3.7% | -171.1% |
| Revenue YoY | 33.4% | — |
| Net Profit YoY | -340.1% | — |
| EPS (diluted) | $-0.01 | $-0.45 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $37.2M | — | ||
| Q3 25 | $30.6M | — | ||
| Q2 25 | $26.8M | — | ||
| Q1 25 | $22.1M | — | ||
| Q4 24 | $27.9M | $57.8M | ||
| Q3 24 | $25.5M | — | ||
| Q2 24 | $25.2M | $28.4M | ||
| Q1 24 | $27.2M | — |
| Q4 25 | $-1.4M | — | ||
| Q3 25 | $5.9M | — | ||
| Q2 25 | $1.6M | — | ||
| Q1 25 | $3.7M | — | ||
| Q4 24 | $569.0K | $-98.8M | ||
| Q3 24 | $2.9M | — | ||
| Q2 24 | $4.5M | $-79.2M | ||
| Q1 24 | $9.9M | — |
| Q4 25 | 95.3% | — | ||
| Q3 25 | 94.7% | — | ||
| Q2 25 | 95.7% | — | ||
| Q1 25 | 95.9% | — | ||
| Q4 24 | 95.8% | 43.1% | ||
| Q3 24 | 96.2% | — | ||
| Q2 24 | 96.9% | 45.8% | ||
| Q1 24 | 96.4% | — |
| Q4 25 | 0.3% | — | ||
| Q3 25 | 22.7% | — | ||
| Q2 25 | 8.1% | — | ||
| Q1 25 | 10.3% | — | ||
| Q4 24 | 2.4% | -155.1% | ||
| Q3 24 | 16.6% | — | ||
| Q2 24 | 12.7% | — | ||
| Q1 24 | 29.7% | — |
| Q4 25 | -3.7% | — | ||
| Q3 25 | 19.4% | — | ||
| Q2 25 | 5.9% | — | ||
| Q1 25 | 16.9% | — | ||
| Q4 24 | 2.0% | -171.1% | ||
| Q3 24 | 11.2% | — | ||
| Q2 24 | 18.0% | -279.4% | ||
| Q1 24 | 36.6% | — |
| Q4 25 | $-0.01 | — | ||
| Q3 25 | $0.03 | — | ||
| Q2 25 | $0.00 | — | ||
| Q1 25 | $0.00 | — | ||
| Q4 24 | $0.00 | $-0.45 | ||
| Q3 24 | $0.01 | — | ||
| Q2 24 | $0.01 | $-0.35 | ||
| Q1 24 | $0.03 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $52.4M | $317.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $106.0M | $860.0M |
| Total Assets | $166.1M | $902.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $52.4M | — | ||
| Q3 25 | $60.0M | — | ||
| Q2 25 | $54.4M | — | ||
| Q1 25 | $29.9M | — | ||
| Q4 24 | $26.7M | $317.2M | ||
| Q3 24 | $25.1M | — | ||
| Q2 24 | $25.1M | $231.8M | ||
| Q1 24 | $37.4M | — |
| Q4 25 | $106.0M | — | ||
| Q3 25 | $101.9M | — | ||
| Q2 25 | $92.0M | — | ||
| Q1 25 | $68.1M | — | ||
| Q4 24 | $63.3M | $860.0M | ||
| Q3 24 | $63.2M | — | ||
| Q2 24 | $60.4M | $870.3M | ||
| Q1 24 | $56.6M | — |
| Q4 25 | $166.1M | — | ||
| Q3 25 | $159.4M | — | ||
| Q2 25 | $152.6M | — | ||
| Q1 25 | $129.8M | — | ||
| Q4 24 | $125.4M | $902.5M | ||
| Q3 24 | $125.2M | — | ||
| Q2 24 | $120.9M | $911.0M | ||
| Q1 24 | $122.0M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.6M | $-18.9M |
| Free Cash FlowOCF − Capex | $-5.8M | $-21.1M |
| FCF MarginFCF / Revenue | -15.5% | -36.5% |
| Capex IntensityCapex / Revenue | 0.4% | 3.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-180.0K | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.6M | — | ||
| Q3 25 | $4.7M | — | ||
| Q2 25 | $2.1M | — | ||
| Q1 25 | $-129.0K | — | ||
| Q4 24 | $-2.8M | $-18.9M | ||
| Q3 24 | $1.7M | — | ||
| Q2 24 | $-5.5M | $-30.7M | ||
| Q1 24 | $2.9M | — |
| Q4 25 | $-5.8M | — | ||
| Q3 25 | $4.0M | — | ||
| Q2 25 | $1.8M | — | ||
| Q1 25 | $-251.0K | — | ||
| Q4 24 | $-2.8M | $-21.1M | ||
| Q3 24 | $1.0M | — | ||
| Q2 24 | $-6.9M | — | ||
| Q1 24 | $2.7M | — |
| Q4 25 | -15.5% | — | ||
| Q3 25 | 13.1% | — | ||
| Q2 25 | 6.8% | — | ||
| Q1 25 | -1.1% | — | ||
| Q4 24 | -10.1% | -36.5% | ||
| Q3 24 | 4.1% | — | ||
| Q2 24 | -27.5% | — | ||
| Q1 24 | 9.8% | — |
| Q4 25 | 0.4% | — | ||
| Q3 25 | 2.2% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 0.6% | — | ||
| Q4 24 | 0.2% | 3.8% | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 5.8% | — | ||
| Q1 24 | 0.9% | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.79× | — | ||
| Q2 25 | 1.32× | — | ||
| Q1 25 | -0.03× | — | ||
| Q4 24 | -4.85× | — | ||
| Q3 24 | 0.60× | — | ||
| Q2 24 | -1.21× | — | ||
| Q1 24 | 0.29× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
